American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis
Bevra H. Hahn,Maureen McMahon,Alan H. Wilkinson,W. Dean Wallace,David I. Daikh,John FitzGerald,George Karpouzas,Joan T. Merrill,Daniel J. Wallace,Jinoos Yazdany,Rosalind Ramsey-Goldman,Karandeep Singh,Mazdak A. Khalighi,Soo I. Choi,Maneesh Gogia,Suzanne Kafaja,Mohammad Kamgar,Christine Lau,William J. Martin,Sefali Parikh,Justin Peng,Anjay Rastogi,Weiling Chen,Jennifer M. Grossman +23 more
TLDR
The management strategies discussed here apply to lupus nephritis in adults, particularly to those receiving care in the United States of America, and include interventions that were available in theUnited States as of April 2011.Abstract:
In the United States, approximately 35% of adults with Systemic Lupus Erythematosus (SLE) have clinical evidence of nephritis at the time of diagnosis; with an estimated total of 50–60% developing nephritis during the first 10 years of disease [1–4]. The prevalence of nephritis is significantly higher in African Americans and Hispanics than in Caucasians, and is higher in men than in women. Renal damage is more likely to develop in non-Caucasian groups [2–4]. Overall survival in patients with SLE is approximately 95% at 5 years after diagnosis and 92% at 10 years [5, 6]. The presence of lupus nephritis significantly reduces survival, to approximately 88% at 10 years, with even lower survival in African Americans [5, 6].
The American College of Rheumatology (ACR) last published guidelines for management of systemic lupus erythematosus (SLE) in 1999 [7]. That publication was designed primarily for education of primary care physicians and recommended therapeutic and management approaches for many manifestations of SLE. Recommendations for management of lupus nephritis (LN) consisted of pulse glucocorticoids followed by high dose daily glucocorticoids in addition to an immunosuppressive medication, with cyclophosphamide viewed as the most effective immunosuppressive medication for diffuse proliferative glomerulonephritis. Mycophenolate mofetil was not yet in use for lupus nephritis and was not mentioned. Since that time, many clinical trials of glucocorticoids-plus-immunosuppressive interventions have been published, some of which are high quality prospective trials, and some not only prospective but also randomized. Thus, the ACR determined that a new set of management recommendations was in order. A combination of extensive literature review and the opinions of highly qualified experts, including rheumatologists, nephrologists and pathologists, has been used to reach the recommendations. The management strategies discussed here apply to lupus nephritis in adults, particularly to those receiving care in the United States of America, and include interventions that were available in the United States as of April 2011.
While these recommendations were developed using rigorous methodology, guidelines do have inherent limitations in informing individual patient care; hence the selection of the term “recommendations.” While they should not supplant clinical judgment or limit clinical judgment, they do provide expert advice to the practicing physician managing patients with lupus nephritis.read more
Citations
More filters
Journal ArticleDOI
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Sixth Special Issue
Joseph E. Schwartz,Jeffrey L. Winters,Anand Padmanabhan,Rasheed A. Balogun,Meghan Delaney,Michael L. Linenberger,Zbigniew M. Szczepiorkowski,Mark E. Williams,Yanyun Wu,Beth H. Shaz +9 more
TL;DR: The Eighth Edition of the JCA Special Issue seeks to continue to serve as a key resource that guides the utilization of TA in the treatment of human disease.
Journal ArticleDOI
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial
Donald P. Tashkin,Michael D. Roth,Philip J. Clements,Daniel E. Furst,Dinesh Khanna,Eric C. Kleerup,Jonathan G. Goldin,Edgar Arriola,Elizabeth R. Volkmann,Suzanne Kafaja,Richard M. Silver,Virginia D. Steen,Charlie Strange,Robert A. Wise,Fredrick M. Wigley,Maureen D. Mayes,David J. Riley,Sabiha Hussain,Shervin Assassi,Vivien Hsu,Bela Patel,Kristine Phillips,Fernando J. Martinez,Jeffrey A. Golden,M. Kari Connolly,John Varga,Jane Dematte,Monique Hinchcliff,Aryeh Fischer,Jeffrey J. Swigris,Richard T. Meehan,Arthur C. Theodore,Robert W. Simms,Suncica Volkov,Dean E. Schraufnagel,Mary Beth Scholand,Tracy M. Frech,Jerry A. Molitor,Kristin B. Highland,Charles A. Read,Marvin J. Fritzler,Grace Kim,Chi-Hong Tseng,Robert Elashoff +43 more
TL;DR: In this article, the authors used a modified intention-to-treat analysis using an inferential joint model combining a mixed-effects model for longitudinal outcomes and a survival model to handle non-ignorable missing data.
Journal ArticleDOI
KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Glomerulonephritis
Laurence H. Beck,Andrew S. Bomback,Michael J. Choi,Lawrence B. Holzman,Carol A. Langford,Laura H. Mariani,Michael J. Somers,Howard Trachtman,Meryl Waldman +8 more
TL;DR: This commentary, developed by a panel of clinical experts convened by the National Kidney Foundation, attempts to put the KDIGO guideline for glomerulonephritis into the context of the US health care system and supports the vast majority of the recommendations.
Journal ArticleDOI
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis
Richard Furie,Brad H. Rovin,Frédéric Houssiau,Ana Malvar,Y K Onno Teng,Gabriel Contreras,Zahir Amoura,Xueqing Yu,Chi Chiu Mok,Mittermayer Barreto Santiago,Amit Saxena,Yulia Green,Beulah Ji,Christi Kleoudis,Susan W Burriss,Carly Barnett,David M. Roth +16 more
TL;DR: In this trial involving patients with active lupus nephritis, more patients who received belimumab plus standard therapy had a primary efficacy renal response than those who received standard therapy alone.
Journal ArticleDOI
The frequency and outcome of lupus nephritis: results from an international inception cohort study
John G. Hanly,Aidan G. O'Keeffe,Li Su,Murray B. Urowitz,Juanita Romero-Diaz,Caroline Gordon,Sang Cheol Bae,Sasha Bernatsky,Ann E. Clarke,Daniel J. Wallace,Joan T. Merrill,David A. Isenberg,Anisur Rahman,Ellen M. Ginzler,Paul R. Fortin,Dafna D. Gladman,Jorge Sanchez-Guerrero,Michelle Petri,Ian N. Bruce,Mary Anne Dooley,Rosalind Ramsey-Goldman,Cynthia Aranow,Graciela S. Alarcón,Barri J. Fessler,Kristjan Steinsson,Ola Nived,Gunnar Sturfelt,Susan Manzi,Munther A. Khamashta,Ronald F van Vollenhoven,Asad Zoma,Manuel Ramos-Casals,Guillermo Ruiz-Irastorza,S. Sam Lim,Thomas Stoll,Murat Inanc,Kenneth C. Kalunian,Diane L. Kamen,Peter J. Maddison,Christine A. Peschken,Søren Jacobsen,Anca Askanase,Chris Theriault,Kara Thompson,Vernon T. Farewell +44 more
TL;DR: Despite current standard of care, nephritis was associated with ESRD and death, and renal insufficiency was linked to lower health-related quality of life.
References
More filters
Journal ArticleDOI
The 1982 revised criteria for the classification of systemic lupus erythematosus
Eng M. Tan,Alan S. Cohen,James F. Fries,Alfonse T. Masi,Dennis J. McShane,Naomi F. Rothfield,Jane G. Schaller,Norman Talal,Robert Winchester +8 more
TL;DR: The 1971 preliminary criteria for the classification of systemic lupus erythematosus (SLE) were revised and updated to incorporate new immunologic knowledge and improve disease classification and showed gains in sensitivity and specificity.
Journal ArticleDOI
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult
Sharon A. Hunt,William T. Abraham,Marshall H. Chin,Arthur M. Feldman,Gary S. Francis,Theodore G. Ganiats,Mariell Jessup,Marvin A. Konstam,Donna Mancini,Keith Michl,John A. Oates,Peter S. Rahko,Marc A. Silver,Lynne W. Stevenson,Clyde W. Yancy,Elliott M. Antman,Sidney C. Smith,Cynthia D. Adams,Jeffrey L. Anderson,David P. Faxon,Valentin Fuster,Jonathan L. Halperin,Loren F. Hiratzka,Alice K. Jacobs,Rick A. Nishimura,Joseph P. Ornato,Richard L. Page,Barbara Riegel +27 more
TL;DR: This document summarizes current capabilities, research and operational priorities, and plans for further studies that were established at the 2015 USGS workshop on quantitative hazard assessments of earthquake-triggered landsliding and liquefaction.
Journal ArticleDOI
ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure).
TL;DR: The American College of Cardiology (ACC)/American Heart Association (AHA) Task Force on Practice Guidelines regularly reviews existing guidelines to determine when an update or full revision is needed.
Journal ArticleDOI
The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited
Jan J. Weening,Vivette D. D'Agati,Melvin M. Schwartz,Surya V. Seshan,Charles E. Alpers,Gerald B. Appel,James E. Balow,Jan A. Bruijn,Terence Cook,Franco Ferrario,Agnes B. Fogo,Ellen M. Ginzler,Lee A. Hebert,Gary Hill,Prue Hill,J. Charles Jennette,Norella C T Kong,Philippe Lesavre,Michael D. Lockshin,Lai-Meng Looi,Hirofumi Makino,Luiz Antonio Ribeiro de Moura,Michio Nagata +22 more
TL;DR: The main advantages of the current revised classification is that it provides a clear and unequivocal description of the various lesions and classes of lupus nephritis, allowing a better standardization and lending a basis for further clinicopathologic studies.
The RAND/UCLA Appropriateness Method User's Manual
TL;DR: The "RAND/UCLA Appropriateness Method" was developed by RAND and UCLA in the 198Os and has been further developed and refined in North America and, increasingly, in Europe.
Related Papers (5)
Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.
The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited
Jan J. Weening,Vivette D. D'Agati,Melvin M. Schwartz,Surya V. Seshan,Charles E. Alpers,Gerald B. Appel,James E. Balow,Jan A. Bruijn,Terence Cook,Franco Ferrario,Agnes B. Fogo,Ellen M. Ginzler,Lee A. Hebert,Gary Hill,Prue Hill,J. Charles Jennette,Norella C T Kong,Philippe Lesavre,Michael D. Lockshin,Lai-Meng Looi,Hirofumi Makino,Luiz Antonio Ribeiro de Moura,Michio Nagata +22 more
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.
Michelle Petri,Ana Maria Orbai,Graciela S. Alarcón,Caroline Gordon,Joan T. Merrill,Paul R. Fortin,Ian N. Bruce,David A. Isenberg,Daniel J. Wallace,Ola Nived,Gunnar Sturfelt,Rosalind Ramsey-Goldman,Sang Cheol Bae,John G. Hanly,Jorge Sanchez-Guerrero,Ann E. Clarke,Cynthia Aranow,Susan Manzi,Murray B. Urowitz,Dafna D. Gladman,Kenneth C. Kalunian,Melissa Costner,Victoria P. Werth,Asad Zoma,Sasha Bernatsky,Guillermo Ruiz-Irastorza,Munther A. Khamashta,Søren Jacobsen,Jill P. Buyon,Peter J. Maddison,Mary Anne Dooley,Ronald F van Vollenhoven,Ellen M. Ginzler,Thomas Stoll,Christine A. Peschken,Joseph L. Jorizzo,Jeffrey P. Callen,S. Sam Lim,Barri J. Fessler,Murat Inanc,Diane L. Kamen,Anisur Rahman,Kristjan Steinsson,Andrew G. Franks,Lisa Sigler,Suhail Hameed,Hong Fang,Ngoc Minh Pham,Robin L. Brey,Michael H. Weisman,Gerald McGwin,Laurence S. Magder +51 more